Drug Profile

Budesonide capsules - AstraZeneca

Alternative Names: Budecol; Budesonide CIR capsule; Budesonide Controlled Ilieal Release capsule; D9421-C; Entocir; Entocord; Entocort; Zentacort

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Developer AstraZeneca; Tillotts Pharma
Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
Mechanism of Action Glucocorticoid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Marketed Crohn's disease; Inflammatory bowel diseases; Microscopic colitis; Proctitis; Ulcerative colitis

23 Feb 2018 Launched for Microscopic colitis in United Kingdom (PO)
05 Feb 2018 Registered for Microscopic colitis in United Kingdom (PO) before February 2018
29 Nov 2016 Launched for Crohn's disease in Japan (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com